Primary Immune Complex Membranoproliferative Glomerulonephritis

SAN DIEGO — Pegcetacoplan may offer a clinical strategy to stabilize kidney function and reduce proteinuria significantly for patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, data show.

Sobi and Apellis Pharmaceuticals Inc. announced results from the phase 3 Valiant study showing the drug pegcetacoplan reduced proteinuria and stabilized eGFR compared to placebo in patients with glomerulopathy or glomerulonephritis.